MEPE has the properties of an osteoblastic phosphatonin and minhibin

P. S.N. Rowe, Y. Kumagai, G. Gutierrez, I. R. Garrett, R. Blacher, D. Rosen, J. Cundy, S. Navvab, D. Chen, M. K. Drezner, Leigh Quarles, G. R. Mundy

Research output: Contribution to journalArticle

206 Citations (Scopus)

Abstract

Matrix extracellular phosphoglycoprotein (MEPE) is expressed exclusively in osteoblasts, osteocytes and odontoblasts with markedly elevated expression found in X-linked hypophosphatemic rickets (Hyp) osteoblasts and in oncogenic hypophosphatemic osteomalacia (OHO) tumors. Because these syndromes are associated with abnormalities in mineralization and renal phosphate excretion, we examined the effects of insect-expressed full-length human-MEPE (Hu-MEPE) on serum and urinary phosphate in vivo, 33PO4 uptake in renal proximal tubule cultures and mineralization of osteoblast cultures. Dose-dependent hypophosphatemia and hyperphosphaturia occurred in mice following intraperitoneal (IP) administration of Hu-MEPE (up to 400 μg kg-1 31 h-1), similar to mice given the phosphaturic hormone PTH (80 μg kg-1 31 h-1). Also the fractional excretion of phosphate (FEP) was stimulated by MEPE [65.0% (P < 0.001)] and PTH groups [53.3% (P < 0.001)] relative to the vehicle group [28.7% (SEM 3.97)]. In addition, Hu-MEPE significantly inhibited 33PO 4 uptake in primary human proximal tubule renal cells (RPTEC) and a human renal cell line (Hu-CL8) in vitro (Vmax 53.4% inhibition; Km 27.4 ng/ml, and Vmax 9.1% inhibition; Km 23.8 ng/ml, respectively). Moreover, Hu-MEPE dose dependently (50-800 ng/ml) inhibited BMP2-mediated mineralization of a murine osteoblast cell line (2T3) in vitro. Inhibition of mineralization was localized to a small (2 kDa) cathepsin B released carboxy-terminal MEPE peptide (protease-resistant) containing the acidic serine-aspartate-rich motif (ASARM peptide). We conclude that MEPE promotes renal phosphate excretion and modulates mineralization.

Original languageEnglish (US)
Pages (from-to)303-319
Number of pages17
JournalBone
Volume34
Issue number2
DOIs
StatePublished - Jan 1 2004

Fingerprint

Extracellular Matrix
Osteoblasts
Phosphates
Proximal Kidney Tubule
Familial Hypophosphatemic Rickets
Familial Hypophosphatemia
Odontoblasts
Hypophosphatemia
Osteocytes
Cell Line
Cathepsin B
Peptides
Aspartic Acid
Serine
Insects
Peptide Hydrolases
Hormones
Kidney
Serum
Neoplasms

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Rowe, P. S. N., Kumagai, Y., Gutierrez, G., Garrett, I. R., Blacher, R., Rosen, D., ... Mundy, G. R. (2004). MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone, 34(2), 303-319. https://doi.org/10.1016/j.bone.2003.10.005

MEPE has the properties of an osteoblastic phosphatonin and minhibin. / Rowe, P. S.N.; Kumagai, Y.; Gutierrez, G.; Garrett, I. R.; Blacher, R.; Rosen, D.; Cundy, J.; Navvab, S.; Chen, D.; Drezner, M. K.; Quarles, Leigh; Mundy, G. R.

In: Bone, Vol. 34, No. 2, 01.01.2004, p. 303-319.

Research output: Contribution to journalArticle

Rowe, PSN, Kumagai, Y, Gutierrez, G, Garrett, IR, Blacher, R, Rosen, D, Cundy, J, Navvab, S, Chen, D, Drezner, MK, Quarles, L & Mundy, GR 2004, 'MEPE has the properties of an osteoblastic phosphatonin and minhibin', Bone, vol. 34, no. 2, pp. 303-319. https://doi.org/10.1016/j.bone.2003.10.005
Rowe PSN, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004 Jan 1;34(2):303-319. https://doi.org/10.1016/j.bone.2003.10.005
Rowe, P. S.N. ; Kumagai, Y. ; Gutierrez, G. ; Garrett, I. R. ; Blacher, R. ; Rosen, D. ; Cundy, J. ; Navvab, S. ; Chen, D. ; Drezner, M. K. ; Quarles, Leigh ; Mundy, G. R. / MEPE has the properties of an osteoblastic phosphatonin and minhibin. In: Bone. 2004 ; Vol. 34, No. 2. pp. 303-319.
@article{351cd7d7391e41e8a03a2301c2709501,
title = "MEPE has the properties of an osteoblastic phosphatonin and minhibin",
abstract = "Matrix extracellular phosphoglycoprotein (MEPE) is expressed exclusively in osteoblasts, osteocytes and odontoblasts with markedly elevated expression found in X-linked hypophosphatemic rickets (Hyp) osteoblasts and in oncogenic hypophosphatemic osteomalacia (OHO) tumors. Because these syndromes are associated with abnormalities in mineralization and renal phosphate excretion, we examined the effects of insect-expressed full-length human-MEPE (Hu-MEPE) on serum and urinary phosphate in vivo, 33PO4 uptake in renal proximal tubule cultures and mineralization of osteoblast cultures. Dose-dependent hypophosphatemia and hyperphosphaturia occurred in mice following intraperitoneal (IP) administration of Hu-MEPE (up to 400 μg kg-1 31 h-1), similar to mice given the phosphaturic hormone PTH (80 μg kg-1 31 h-1). Also the fractional excretion of phosphate (FEP) was stimulated by MEPE [65.0{\%} (P < 0.001)] and PTH groups [53.3{\%} (P < 0.001)] relative to the vehicle group [28.7{\%} (SEM 3.97)]. In addition, Hu-MEPE significantly inhibited 33PO 4 uptake in primary human proximal tubule renal cells (RPTEC) and a human renal cell line (Hu-CL8) in vitro (Vmax 53.4{\%} inhibition; Km 27.4 ng/ml, and Vmax 9.1{\%} inhibition; Km 23.8 ng/ml, respectively). Moreover, Hu-MEPE dose dependently (50-800 ng/ml) inhibited BMP2-mediated mineralization of a murine osteoblast cell line (2T3) in vitro. Inhibition of mineralization was localized to a small (2 kDa) cathepsin B released carboxy-terminal MEPE peptide (protease-resistant) containing the acidic serine-aspartate-rich motif (ASARM peptide). We conclude that MEPE promotes renal phosphate excretion and modulates mineralization.",
author = "Rowe, {P. S.N.} and Y. Kumagai and G. Gutierrez and Garrett, {I. R.} and R. Blacher and D. Rosen and J. Cundy and S. Navvab and D. Chen and Drezner, {M. K.} and Leigh Quarles and Mundy, {G. R.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.bone.2003.10.005",
language = "English (US)",
volume = "34",
pages = "303--319",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - MEPE has the properties of an osteoblastic phosphatonin and minhibin

AU - Rowe, P. S.N.

AU - Kumagai, Y.

AU - Gutierrez, G.

AU - Garrett, I. R.

AU - Blacher, R.

AU - Rosen, D.

AU - Cundy, J.

AU - Navvab, S.

AU - Chen, D.

AU - Drezner, M. K.

AU - Quarles, Leigh

AU - Mundy, G. R.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Matrix extracellular phosphoglycoprotein (MEPE) is expressed exclusively in osteoblasts, osteocytes and odontoblasts with markedly elevated expression found in X-linked hypophosphatemic rickets (Hyp) osteoblasts and in oncogenic hypophosphatemic osteomalacia (OHO) tumors. Because these syndromes are associated with abnormalities in mineralization and renal phosphate excretion, we examined the effects of insect-expressed full-length human-MEPE (Hu-MEPE) on serum and urinary phosphate in vivo, 33PO4 uptake in renal proximal tubule cultures and mineralization of osteoblast cultures. Dose-dependent hypophosphatemia and hyperphosphaturia occurred in mice following intraperitoneal (IP) administration of Hu-MEPE (up to 400 μg kg-1 31 h-1), similar to mice given the phosphaturic hormone PTH (80 μg kg-1 31 h-1). Also the fractional excretion of phosphate (FEP) was stimulated by MEPE [65.0% (P < 0.001)] and PTH groups [53.3% (P < 0.001)] relative to the vehicle group [28.7% (SEM 3.97)]. In addition, Hu-MEPE significantly inhibited 33PO 4 uptake in primary human proximal tubule renal cells (RPTEC) and a human renal cell line (Hu-CL8) in vitro (Vmax 53.4% inhibition; Km 27.4 ng/ml, and Vmax 9.1% inhibition; Km 23.8 ng/ml, respectively). Moreover, Hu-MEPE dose dependently (50-800 ng/ml) inhibited BMP2-mediated mineralization of a murine osteoblast cell line (2T3) in vitro. Inhibition of mineralization was localized to a small (2 kDa) cathepsin B released carboxy-terminal MEPE peptide (protease-resistant) containing the acidic serine-aspartate-rich motif (ASARM peptide). We conclude that MEPE promotes renal phosphate excretion and modulates mineralization.

AB - Matrix extracellular phosphoglycoprotein (MEPE) is expressed exclusively in osteoblasts, osteocytes and odontoblasts with markedly elevated expression found in X-linked hypophosphatemic rickets (Hyp) osteoblasts and in oncogenic hypophosphatemic osteomalacia (OHO) tumors. Because these syndromes are associated with abnormalities in mineralization and renal phosphate excretion, we examined the effects of insect-expressed full-length human-MEPE (Hu-MEPE) on serum and urinary phosphate in vivo, 33PO4 uptake in renal proximal tubule cultures and mineralization of osteoblast cultures. Dose-dependent hypophosphatemia and hyperphosphaturia occurred in mice following intraperitoneal (IP) administration of Hu-MEPE (up to 400 μg kg-1 31 h-1), similar to mice given the phosphaturic hormone PTH (80 μg kg-1 31 h-1). Also the fractional excretion of phosphate (FEP) was stimulated by MEPE [65.0% (P < 0.001)] and PTH groups [53.3% (P < 0.001)] relative to the vehicle group [28.7% (SEM 3.97)]. In addition, Hu-MEPE significantly inhibited 33PO 4 uptake in primary human proximal tubule renal cells (RPTEC) and a human renal cell line (Hu-CL8) in vitro (Vmax 53.4% inhibition; Km 27.4 ng/ml, and Vmax 9.1% inhibition; Km 23.8 ng/ml, respectively). Moreover, Hu-MEPE dose dependently (50-800 ng/ml) inhibited BMP2-mediated mineralization of a murine osteoblast cell line (2T3) in vitro. Inhibition of mineralization was localized to a small (2 kDa) cathepsin B released carboxy-terminal MEPE peptide (protease-resistant) containing the acidic serine-aspartate-rich motif (ASARM peptide). We conclude that MEPE promotes renal phosphate excretion and modulates mineralization.

UR - http://www.scopus.com/inward/record.url?scp=10744226781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226781&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2003.10.005

DO - 10.1016/j.bone.2003.10.005

M3 - Article

VL - 34

SP - 303

EP - 319

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -